$OSUR
ORASURE TECHNOLOGIES INC

2016 Q4 Form 10-Q Financial Statement

#000119312516762972 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $35.50M $32.25M $32.38M
YoY Change 9.63% 8.0% 12.9%
Cost Of Revenue $11.55M $9.576M $10.45M
YoY Change 10.53% 4.18% -2.43%
Gross Profit $23.95M $22.68M $21.93M
YoY Change 9.21% 9.71% 21.97%
Gross Profit Margin 67.47% 70.31% 67.72%
Selling, General & Admin $15.67M $13.34M $15.15M
YoY Change 3.43% -19.71% -9.39%
% of Gross Profit 65.43% 58.81% 69.08%
Research & Development $1.210M $3.196M $2.690M
YoY Change -55.02% 26.57% -29.58%
% of Gross Profit 5.05% 14.09% 12.27%
Depreciation & Amortization $1.490M $1.414M $1.440M
YoY Change 3.47% 0.28% -8.86%
% of Gross Profit 6.22% 6.24% 6.57%
Operating Expenses $16.88M $16.53M $17.84M
YoY Change -5.38% -13.6% -13.1%
Operating Profit $7.073M $6.144M $4.092M
YoY Change 72.85% 300.0% -259.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $92.00K $498.0K $379.0K
YoY Change -75.73% 514.81% 32.06%
Pretax Income $7.165M $6.642M $4.471M
YoY Change 60.25% 310.76% -296.44%
Income Tax -$31.00K $400.0K -$145.0K
% Of Pretax Income -0.43% 6.02% -3.24%
Net Earnings $7.196M $6.242M $4.616M
YoY Change 55.89% 324.63% -274.06%
Net Earnings / Revenue 20.27% 19.35% 14.25%
Basic Earnings Per Share $0.13 $0.11 $0.08
Diluted Earnings Per Share $0.13 $0.11 $0.08
COMMON SHARES
Basic Shares Outstanding 55.73M shares 55.65M shares 56.48M shares
Diluted Shares Outstanding 56.53M shares

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.1M $119.3M $101.3M
YoY Change 17.57% 10.26% 3.47%
Cash & Equivalents $108.0M $111.7M $94.09M
Short-Term Investments $11.20M $7.600M $7.200M
Other Short-Term Assets $2.143M $660.0K $1.355M
YoY Change 58.15% 315.09% 342.81%
Inventory $11.80M $12.07M $13.24M
Prepaid Expenses $1.722M $1.364M $1.533M
Receivables $19.83M $15.47M $19.27M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $156.4M $150.7M $136.7M
YoY Change 14.43% 6.27% 4.19%
LONG-TERM ASSETS
Property, Plant & Equipment $20.03M $20.07M $20.08M
YoY Change -0.25% 12.75% 11.98%
Goodwill $18.79M $19.24M $18.25M
YoY Change 2.98% 1.42% -16.03%
Intangibles $10.34M $11.21M $12.59M
YoY Change -17.9% -17.98% -28.07%
Long-Term Investments
YoY Change
Other Assets $2.331M $2.322M $1.683M
YoY Change 38.5% 46.13% 35.07%
Total Long-Term Assets $51.49M $52.84M $52.61M
YoY Change -2.12% 1.57% -9.95%
TOTAL ASSETS
Total Short-Term Assets $156.4M $150.7M $136.7M
Total Long-Term Assets $51.49M $52.84M $52.61M
Total Assets $207.9M $203.6M $189.3M
YoY Change 9.83% 5.01% -0.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.633M $4.422M $5.087M
YoY Change -8.92% -36.5% -28.83%
Accrued Expenses $11.31M $9.618M $10.41M
YoY Change 8.66% 3.34% -6.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.34M $21.95M $25.23M
YoY Change -31.3% -26.08% -4.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.304M $2.289M $1.768M
YoY Change 30.32% 100.44% 43.27%
Total Long-Term Liabilities $2.304M $2.289M $1.768M
YoY Change 30.32% 100.44% 43.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.34M $21.95M $25.23M
Total Long-Term Liabilities $2.304M $2.289M $1.768M
Total Liabilities $19.64M $24.24M $27.00M
YoY Change -27.27% -21.39% -2.51%
SHAREHOLDERS EQUITY
Retained Earnings -$150.5M -$157.7M -$170.2M
YoY Change -11.59% -9.81% -4.58%
Common Stock $350.5M $347.3M $345.3M
YoY Change 1.53% -0.4% 0.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.9M $176.5M $159.4M
YoY Change
Total Liabilities & Shareholders Equity $207.9M $203.6M $189.3M
YoY Change 9.83% 5.01% -0.16%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income $7.196M $6.242M $4.616M
YoY Change 55.89% 324.63% -274.06%
Depreciation, Depletion And Amortization $1.490M $1.414M $1.440M
YoY Change 3.47% 0.28% -8.86%
Cash From Operating Activities -$580.0K $8.440M $660.0K
YoY Change -187.88% -54.45% -177.65%
INVESTING ACTIVITIES
Capital Expenditures -$840.0K $783.0K -$1.850M
YoY Change -54.59% 5.81% 180.3%
Acquisitions
YoY Change
Other Investing Activities -$3.710M $0.00 $0.00
YoY Change
Cash From Investing Activities -$4.560M -$780.0K -$1.860M
YoY Change 145.16% 5.41% 186.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.620M 320.0K -4.930M
YoY Change -132.86% -964.91%
NET CHANGE
Cash From Operating Activities -580.0K 8.440M 660.0K
Cash From Investing Activities -4.560M -780.0K -1.860M
Cash From Financing Activities 1.620M 320.0K -4.930M
Net Change In Cash -3.520M 7.980M -6.130M
YoY Change -42.58% -55.14% 559.14%
FREE CASH FLOW
Cash From Operating Activities -$580.0K $8.440M $660.0K
Capital Expenditures -$840.0K $783.0K -$1.850M
Free Cash Flow $260.0K $7.657M $2.510M
YoY Change -89.64% -56.96% -1421.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2008Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
25000000
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55730629 shares
CY2016Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
1810000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100677000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-6036000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5547000
CY2016Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
26015000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35264
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55723000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55723000 shares
CY2016Q3 us-gaap Assets
Assets
203558000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
150719000
CY2016Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
610000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
347274000
CY2016Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
633000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111726000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15471000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4422000
CY2016Q3 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1888000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7911000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1370000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2501000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13138000
CY2016Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2836000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9618000
CY2016Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6832000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14810000
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
660000
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11205000
CY2016Q3 us-gaap Inventory Net
InventoryNet
12070000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203558000
CY2016Q3 us-gaap Goodwill
Goodwill
19243000
CY2016Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1190000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2289000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21951000
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1364000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2091000
CY2016Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2016Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4048000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2322000
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20069000
CY2016Q3 us-gaap Short Term Investments
ShortTermInvestments
7618000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
176482000
CY2016Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
1810000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157654000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92867000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6311000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24950000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33013
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55705000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55705000 shares
CY2015Q4 us-gaap Assets
Assets
189321000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
136714000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
819000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345253000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
798000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94094000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19265000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5087000
CY2015Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1324000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9735000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15639000
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2883000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10412000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7895000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12359000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1355000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12591000
CY2015Q4 us-gaap Inventory Net
InventoryNet
13242000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189321000
CY2015Q4 us-gaap Goodwill
Goodwill
18250000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
333000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1768000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25234000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1533000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2268000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5014000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1683000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20083000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
7225000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
159436000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170178000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2485000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
28974000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
729000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-450000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Operating Expenses
OperatingExpenses
54397000
us-gaap Net Income Loss
NetIncomeLoss
3551000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4361000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4846000
CY2015Q2 osur Contract Expiration Period
ContractExpirationPeriod
P3Y
CY2015Q2 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
8600000
CY2015Q2 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
1800000
CY2015Q2 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
10400000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
612000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7810000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1690000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18971000
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4259000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
198000
us-gaap Revenues
Revenues
87337000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
395000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1540000
us-gaap Gross Profit
GrossProfit
58363000
us-gaap Income Taxes Paid
IncomeTaxesPaid
230000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6036000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
16450000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1572000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
883000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-72000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
614000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-633000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
473000 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
3966000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-759000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19411000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5269000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
11545000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
810000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
15105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1885000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
75792000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56427000 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8961000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
124000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26465000
us-gaap Share Based Compensation
ShareBasedCompensation
4543000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
76000
dei Entity Registrant Name
EntityRegistrantName
ORASURE TECHNOLOGIES INC
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
839000
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001116463
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17632000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
558000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19803000
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4212000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15025000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2467000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
28626000
us-gaap Contracts Revenue
ContractsRevenue
12837000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-564000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-75000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-205000
us-gaap Revenues
Revenues
92699000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-90000
us-gaap Gross Profit
GrossProfit
64073000
us-gaap Income Taxes Paid
IncomeTaxesPaid
812000
us-gaap Operating Expenses
OperatingExpenses
50881000
us-gaap Net Income Loss
NetIncomeLoss
12524000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13158000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3512000
us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.00375 pure
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2501000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
367000
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
1081000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
22966000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3818000
us-gaap Line Of Credit Facility Collateral
LineOfCreditFacilityCollateral
Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-09-30
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3311000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-125000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1186000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1236000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
724000 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
13192000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2784000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22966000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1829000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
14413000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
634000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
23370000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3512000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1810000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Use of Estimates</u>.</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management&#x2019;s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</p> </div>
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
78286000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56273000 shares
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
253000
us-gaap Revenue Recognition Sales Returns
RevenueRecognitionSalesReturns
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Customer Sales Returns and Allowances</u>.</i> We do not grant return rights to our customers for any product, except for our OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September&#xA0;30, 2016 and December&#xA0;31, 2015, the reserve for sales returns and allowances was $253 and $310, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product&#x2019;s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.</p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55549000 shares
dei Trading Symbol
TradingSymbol
OSUR
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8547000
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Deferred Revenue</u>.</i> We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September&#xA0;30, 2016 and December&#xA0;31, 2015 includes customer prepayments of $1,797 and $784, respectively. Deferred revenue as of September&#xA0;30, 2016 and December&#xA0;31, 2015 also includes $6,114 and $8,951, respectively, from AbbVie, which represents the excess of the payments received from AbbVie over the amounts earned and recognized ratably in our consolidated statements of income.</p> </div>
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
894000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22531000
us-gaap Share Based Compensation
ShareBasedCompensation
4438000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
241000
osur Rights Agreement Expiration Date
RightsAgreementExpirationDate
2019-12-31
osur Amortization Accretion Of Lease Incentives
AmortizationAccretionOfLeaseIncentives
-60000
CY2015Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
7200000
CY2016Q3 osur Contract Expiration Period
ContractExpirationPeriod
P6Y
CY2016Q3 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
9600000
CY2016Q3 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
7000000
CY2016Q3 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
16600000
CY2015 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
310000
CY2015Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
315000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6931000
CY2015Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1410000
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1388000
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9192000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
188000
CY2015Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-168000
CY2015Q3 us-gaap Revenues
Revenues
29861000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81000
CY2015Q3 us-gaap Gross Profit
GrossProfit
20669000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
19133000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
1470000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1617000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2858000
CY2015Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
210000 shares
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1536000
CY2015Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
4147000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
147000
CY2015Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
740000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25714000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56692000 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56482000 shares
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2525000
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9677000
CY2016Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
561000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6907000
CY2016Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1434000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2016Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
6791000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5513000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9576000
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
6114000
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
84000
CY2016Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-161000
CY2016Q3 us-gaap Revenues
Revenues
32251000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
498000
CY2016Q3 us-gaap Gross Profit
GrossProfit
22675000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
16531000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
6242000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6642000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-729000
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
877000 shares
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6144000
CY2016Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
783000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25460000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56530000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55653000 shares
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3196000
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6428000
CY2016Q3 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
203000

Files In Submission

Name View Source Status
0001193125-16-762972-index-headers.html Edgar Link pending
0001193125-16-762972-index.html Edgar Link pending
0001193125-16-762972.txt Edgar Link pending
0001193125-16-762972-xbrl.zip Edgar Link pending
d281107d10q.htm Edgar Link pending
d281107dex10.htm Edgar Link pending
d281107dex311.htm Edgar Link pending
d281107dex312.htm Edgar Link pending
d281107dex321.htm Edgar Link pending
d281107dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g281107weelsfar.jpg Edgar Link pending
osur-20160930.xml Edgar Link completed
osur-20160930.xsd Edgar Link pending
osur-20160930_cal.xml Edgar Link unprocessable
osur-20160930_def.xml Edgar Link unprocessable
osur-20160930_lab.xml Edgar Link unprocessable
osur-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending